You’ve probably seen the headlines. CVS Health is constantly in the news, and usually, it's about something messy. One day it’s a massive leadership shakeup, the next it’s another multi-billion dollar impairment charge. It's enough to make any sane investor dizzy. But if you’re looking at cvs stock buy or sell options right now, you need to look past the surface-level chaos of 2024 and 2025.
The reality? This isn't just a "drugstore" anymore. It’s a massive, integrated healthcare beast that's finally starting to find its footing after a very awkward teenage growth spurt.
What's Actually Moving the Needle for CVS?
Honestly, the retail pharmacy part of the business—the stuff we see every day—is almost secondary to the real money-makers. We’re talking about Aetna (the insurance arm) and Caremark (the pharmacy benefit manager). These two segments are the actual engines under the hood.
Last year was rough for Aetna. Medical costs went through the roof, and the "Medical Benefit Ratio" (MBR) was basically a horror show for shareholders. But things are shifting. In late 2025, CVS boosted its guidance because Aetna finally started returning to its target margins. That’s a huge deal. When an insurance company gets its costs under control, the cash flow follows.
- Medicare Advantage Win: Over 81% of Aetna’s Medicare Advantage members are now in 4-star plans or higher for 2026. Higher stars mean higher government payouts. It’s basically "free" money from Uncle Sam for being good at what they do.
- The ACA Exit: CVS made a bold move by deciding to exit the Affordable Care Act (ACA) individual exchange business in 2026. Why? Because it wasn't profitable enough. They’re cutting the dead weight to focus on high-margin sectors.
- New Leadership: David Joyner took over as CEO, and Brian Newman (formerly of UPS) stepped in as CFO. They aren't just "holding the fort." They’re aggressively cutting costs, including a $1.2 billion restructuring plan that involved closing underperforming stores.
CVS Stock Buy or Sell: Decoding the Numbers
Wall Street is cautiously optimistic, which is usually the best time to buy if you have a long-term stomach. As of January 2026, the consensus is sitting at a "Moderate Buy." Analysts from firms like JPMorgan and Piper Sandler have been nudging their price targets upward, with some looking at the $101 mark.
✨ Don't miss: Rough Tax Return Calculator: How to Estimate Your Refund Without Losing Your Mind
Wait. Is it cheap?
Relative to its peers, CVS looks like a bargain-bin find. While UnitedHealth (UNH) and Elevance (ELV) often trade at much higher multiples, CVS has been beaten down by its own internal drama. For 2026, the company is guiding for an adjusted EPS (earnings per share) between $7.00 and $7.20. If they hit that, the current price starts to look very attractive.
The Dividend Safety Net
If you like getting paid to wait, the dividend is a strong argument for the "buy" side. They just reaffirmed a quarterly dividend of $0.665 per share. That’s an annualized yield of around 3.3%. It’s not "get rich quick" money, but it’s consistent. Plus, they’re projecting at least $10 billion in cash flow from operations for 2026. That’s a lot of ammo for dividends and debt reduction.
The Bear Case: What Could Go Wrong?
I’m not going to sit here and tell you it’s all sunshine. There are real risks.
🔗 Read more: Replacement Walk In Cooler Doors: What Most People Get Wrong About Efficiency
Regulatory scrutiny on Pharmacy Benefit Managers (PBMs) is intense. Politicians on both sides of the aisle love to beat up on PBMs like Caremark, blaming them for high drug prices. If new legislation actually passes that guts their ability to negotiate rebates, a huge chunk of CVS’s profit could vanish.
Then there's the retail side. Amazon Pharmacy is still a looming shadow, and Mark Cuban’s Cost Plus Drugs is nipping at their heels. CVS is fighting back by launching "engagement as a service" and making their app AI-native to keep people in their ecosystem, but it's an uphill battle. People don't love going to the pharmacy. They do it because they have to.
The "Wegovy" Factor
Here’s a detail many people miss: CVS struck a deal with Novo Nordisk to sell Wegovy (the weight-loss drug) at a discounted cash price of around $499 a month. In a world obsessed with GLP-1s, being the go-to provider for these high-demand drugs is a savvy move. It drives foot traffic and high-volume sales, even if the margins on the drug itself aren't astronomical.
Actionable Strategy for Investors
If you’re looking at cvs stock buy or sell through the lens of 2026, here is the move.
💡 You might also like: Share Market Today Closed: Why the Benchmarks Slipped and What You Should Do Now
CVS is a classic turnaround play. It’s not for the person who wants to see 20% growth in a month. It’s for the person who sees a company generating $400 billion in revenue—yes, that’s billion with a "B"—and realizes the market is currently pricing it like it's going out of business.
- Watch the February Earnings: The Q4 2025 call on February 10, 2026, will be the first major test for the new leadership's 2026 guidance.
- Monitor the MBR: If Aetna’s medical costs stay low, the stock will likely re-rate higher.
- Income Play: If you’re a dividend investor, buying on dips below $80 has historically been a solid entry point.
The bottom line is simple. The "messy" years of integrating Aetna and Oak Street Health are mostly in the rearview mirror. What's left is a diversified healthcare giant that is finally focused on profitability over pure expansion.
Next Steps for You:
Check your portfolio allocation for healthcare. If you're underweight, CVS offers a value-priced entry compared to the broader S&P 500. You should also review the upcoming February 10th earnings transcript to see if they're hitting their $10 billion cash flow targets.